|
|
Vaccine Detail
|
HPV16 E6/E7 Melanoma Vaccine |
| Vaccine Information |
- Vaccine Name: HPV16 E6/E7 Melanoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Research
- Host Species for Licensed Use: None
- Antigen: human papillomavirus (HPV)-16 E7 antigen (Kuai et al., 2020)
- Immunization Route: subcutaneous injection
- Description: Subcutaneous vaccination with nanodiscs carrying human papillomavirus (HPV)-16 E7 antigen elicits as high as ~32% E7-specific CD8 α + T cell responses in circulation. Nanodisc vaccination also promotes robust intratumoral T cell infiltration and eliminates HPV16 E6/E7-expressing TC-1 tumors at mucosal sites, including lungs, inner lip, and intravaginal tissues. Nanodisc vaccination in HLA-A02 mice generates a stronger IFN-γ+ T cell responses against a neoantigen from an HLA-A02 melanoma patient. The nanodisc system is a promising cancer vaccine platform for inducing anti-tumor T cell responses. (Kuai et al., 2020)
|
| Host Response |
|
|
| References |
Kuai et al., 2020: Kuai R, Singh PB, Sun X, Xu C, Najafabadi AH, Scheetz L, Yuan W, Xu Y, Hong H, Keskin DB, Wu CJ, Jain R, Schwendeman A, Moon JJ. Robust anti-tumor T cell response with efficient intratumoral infiltration by nanodisc cancer immunotherapy. Advanced therapeutics. 2020; 3(9); . [PubMed: 38317797].
|
|
